The SwRI technologies employ a controlled and continuous atomizing technology that Flexion believes may facilitate efficient scale-up of Phase III clinical trial material and commercial supply.
The company has successfully used this technology to produce clinical trial microsphere product for its lead drug candidate FX006, which has been tested in over 200 patients.
Flexion president and CEO Michael Clayman said the exclusive license for this patented manufacturing technology provides the company another layer of intellectual property protection for its lead product candidate FX006 and will complement the patent for FX006, which it anticipates will issue within the next six to 12 months.
"In addition, this agreement provides for an expanded field of use in a variety of musculoskeletal disorders, which offers us flexibility to explore different diseases where sustained-release technology could be useful for patients," Clayman said.